Research Group
Prostate and Urologic Cancer
Sponsor
Rapamycin Holdings, Inc. dba Emtora Biosciences
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT04375813
eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized controlled trial of long-term (one year) prevention with eRapa versus placebo. The primary hypothesis is that eRapa decreases the risk of cancer relapse for patients with NMIBC. Secondary hypotheses are that eRapa can improve certain immune parameters and improve cognition and physical function without adversely affecting patient-reported outcomes and quality of life.
Intervention
Placebos, eRapa
Condition
Non-muscle Invasive Bladder Cancer
Investigators
Robert S Svatek, MD, MSCI, Robert S Svatek, MD, Michael A Liss, MD, Yair Lotan, MD, Ahmed Mansour, MD, Jessie Williams, A, Donna Mitchell, Fred Norton, BS